Intercept Pharmaceuticals

This study tested whether combining two drugs, obeticholic acid and bezafibrate, could improve liver health in people with primary biliary cholangitis (PBC) who did not respond well to standard treatment. About 75 adults with PBC were enrolled. The study was stopped early, so res…

This study tested a new medicine called INT-787 for people with severe alcohol-associated hepatitis, a serious liver condition. The trial aimed to see if the drug was safe and could improve liver function. It included 67 adults who drank heavily and had jaundice. The study was st…

This study looked at the long-term safety of a fixed-dose combination of two drugs, obeticholic acid and bezafibrate, in adults with primary biliary cholangitis (PBC), a chronic liver disease. It enrolled 63 participants who had previously been in related studies. The study was t…

This study tested a drug called obeticholic acid in children with biliary atresia who had a Kasai surgery. The goal was to see if the drug could delay serious liver problems like the need for a transplant or death. The trial was stopped early, and it involved 28 children from bir…